CV Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

6. ACQUISITIONS (Tables)

12 Months Ended

Dec. 31, 2015

Cash consideration	$	250,000
Company common stock		1,150,000
Contingent purchase price liability		250,000
Contingent purchase price equity		3,489,000
Aggregate consideration	$	5,139,000

The purchase price was allocated as follows:
In-process research and development	$	3,730,000
Trade names		100,000
Non-compete agreements		77,000
Deferred tax liability		(1,556,300	)
Goodwill		2,788,300
Total purchase price allocation	$	5,139,000